Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002629390 | SCV003518706 | likely pathogenic | Mucopolysaccharidosis type 1 | 2022-10-18 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. This variant disrupts the p.Glu182 amino acid residue in IDUA. Other variant(s) that disrupt this residue have been observed in individuals with IDUA-related conditions (PMID: 21480867), which suggests that this may be a clinically significant amino acid residue. Experimental studies have shown that this missense change affects IDUA function (PMID: 11555618, 33198351). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt IDUA protein function. This missense change has been observed in individuals with mucopolysaccharidosis type I (PMID: 11555618, 24368159). This variant is present in population databases (rs754154200, gnomAD 0.0009%). This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 182 of the IDUA protein (p.Glu182Lys). |